Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2014.55.347
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Mirjana Babić
orcid.org/0000-0003-4223-4190
; Department of Neuroscience Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia
Dubravka Švob Štrac
orcid.org/0000-0001-6200-2405
; Division of Molecular Medicine Ruđer Bošković Institute, Zagreb Croatia
Dorotea Mück-Šeler
; Division of Molecular Medicine Ruđer Bošković Institute, Zagreb Croatia
Nela Pivac
orcid.org/0000-0003-3591-4868
; Division of Molecular Medicine Ruđer Bošković Institute, Zagreb Croatia
Gabrijela Stanić
; Department of Pathology and Cytology, “Sveti Duh” Clinical Hospital, Zagreb, Croatia
Patrick R. Hof
; Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Goran Šimić
orcid.org/0000-0002-6339-9261
; Department of Neuroscience Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia
Sažetak
Alzheimer disease (AD) is a complex neurodegenerative
disorder, whose prevalence will dramatically rise by 2050.
Despite numerous clinical trials investigating this disease,
there is still no effective treatment. Many trials showed
negative or inconclusive results, possibly because they recruited
only patients with severe disease, who had not undergone
disease-modifying therapies in preclinical stages
of AD before severe degeneration occurred. Detection of
AD in asymptomatic at risk individuals (and a few presymptomatic
individuals who carry an autosomal dominant monogenic
AD mutation) remains impractical in many of clinical
situations and is possible only with reliable biomarkers.
In addition to early diagnosis of AD, biomarkers should
serve for monitoring disease progression and response to
therapy. To date, the most promising biomarkers are cerebrospinal
fluid (CSF) and neuroimaging biomarkers. Core
CSF biomarkers (amyloid β1-42, total tau, and phosphorylated
tau) showed a high diagnostic accuracy but were still
unreliable for preclinical detection of AD. Hence, there is
an urgent need for detection and validation of novel CSF
biomarkers that would enable early diagnosis of AD in
asymptomatic individuals. This article reviews recent research
advances on biomarkers for AD, focusing mainly on
the CSF biomarkers. In addition to core CSF biomarkers, the
potential usefulness of novel CSF biomarkers is discussed.
Ključne riječi
Hrčak ID:
129941
URI
Datum izdavanja:
15.8.2014.
Posjeta: 1.479 *